What is Biosceptre?
Biosceptre is at the forefront of developing advanced cancer treatments, focusing on a novel multiple-targeted universal CAR T system. Their proprietary BRiDGECAR system integrates nfP2X-targeted CAR T cells with multiple antibodies, a strategy designed to broaden treatment applicability across a wide range of cancer types, including both liquid and solid tumors. This innovative approach aims to establish best-in-class therapies and significantly improve patient outcomes.
How much funding has Biosceptre raised?
Biosceptre has raised a total of $16M across 3 funding rounds:
Unspecified
$4.7M
Private Equity
$671K
Series A
$10.7M
Unspecified (2014): $4.7M, investors not publicly disclosed
Private Equity (2015): $671K, investors not publicly disclosed
Series A (2017): $10.7M supported by Tuspark Science and Technology Service Group
Key Investors in Biosceptre
Tuspark Science and Technology Service Group
Tus-Holdings Co., Ltd. is a large integrated enterprise established in reliance on Tsinghua University, managing a vast portfolio of technology and innovation-focused companies. Their investment in Biosceptre suggests a strategic interest in cutting-edge biotechnology and therapeutic development.
What's next for Biosceptre?
The recent major strategic investment signals a pivotal growth phase for Biosceptre, likely enabling the company to accelerate its research and development pipelines, expand clinical trials, and potentially scale its manufacturing capabilities. This capital infusion is expected to propel Biosceptre closer to bringing its promising cancer therapies to market, reinforcing its position in the competitive oncology landscape.
See full Biosceptre company page
